Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496210 · ClinicalTrials.gov registry record
Predictors of Caregiver Adaptation to Pervasive Developmental Disorders
A clinical trial of Autism and Asperger's Syndrome, sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- 324
- Enrollment target
- 1
- Study location
NCT00496210: Completed study of Autism and Asperger's Syndrome, sponsored by National Human Genome Research Institute (NHGRI).
NCT00496210 is a study of Autism and Asperger's Syndrome that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 324 participants, above the 180-participant average among 104 other Autism trials with a reported enrollment target (80% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00496210, a study of Autism and Asperger's Syndrome, has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- 324 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will explore predictors of how caregivers might adapt to children diagnosed with a pervasive developmental disorder (PDD), including autism, Asperger s syndrome, childhood disintegrative disorder, Rett s disorder or other not specified PDD. PDD presents particular challenges for caregivers because of the communication and socialization challenges of affected children and because of the uncertainty surrounding the cause, prognosis and recurrence risks. People 18 years of age or older who are the primary caregiver for a child diagnosed with a PDD may be eligible for this study. Participants fill out a survey, either online or in hard copy, that includes information in the following categories: * How being a caregiver for a child with a PDD has impacted the caregiver. * How much control the caregiver feels that he or she or others have over certain aspects of their child s PDD. * What the caregiver thinks caused the child s PDD. * What coping techniques the caregiver uses in caring for a child with a PDD. * How uncertain the caregiver feels about his or her child s PDD. * What the caregiver feels about him- or herself as a caregiver of a child with a PDD. * General questions about the caregiver, his or her family and the child with a PDD.
Conditions Studied
Study Locations (1)
Maryland
- National Human Genome Research Institute (NHGRI), 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2007-06-27 |
| Est. Completion | 2015-12-07 |
What the finished NCT00496210 record still lists
NCT00496210 is an observational study that tracks outcomes without assigning an intervention. The registered 324 participants enrollment target is mid-sized for trials with a published cap, above the 180-participant average among 104 other Autism trials with a reported enrollment target (80% higher).
The record links to 3 conditions, with Autism appearing as the primary indexed condition, and to 0 interventions.
NCT00496210 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00496210 about?
NCT00496210 is a clinical study titled "Predictors of Caregiver Adaptation to Pervasive Developmental Disorders". This study will explore predictors of how caregivers might adapt to children diagnosed with a pervasive developmental disorder (PDD), including autism, Asperger s syndrome, childhood disintegrative disorder, Rett s disorder or other not specified PDD. PDD presents particular challenges for caregiver...
What is the current status of trial NCT00496210?
This trial is currently completed. The enrollment target is 324 participants. The study started on 2007-06-27. Estimated completion is 2015-12-07.
What conditions does trial NCT00496210 study?
This clinical trial studies the following conditions: Autism, Asperger's Syndrome, Rett's Disorder.
Who is sponsoring clinical trial NCT00496210?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00496210 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00496210's enrollment target sits among peer trials
324 10th of 104 higher than 95 of 104 other Autism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
RECRUITING · NA
-
Cerebellum and Autism: Regional Specialization for Social and Executive Functions
RECRUITING · NA
-
Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth
RECRUITING · NA
-
Examining the Effectiveness of the Early Start Denver Model in Community Programs Serving Young Autism
RECRUITING · NA
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI